NCT01393145View on ClinicalTrials.gov

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Chronic Obstructive Pulmonary DiseaseCOPD
Interventions
DRUG

Combination Fluticasone /Formoterol 12/250 μg

Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®

DRUG

Seretide Diskus (salmeterol/fluticasone) 50/250 μg

Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses

Sponsors
All Listed Sponsors
lead

Ache Laboratorios Farmaceuticos S.A.

INDUSTRY

NCT01393145 - Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD | Biotech Hunter | Biotech Hunter